We are dedicated to safely providing new treatment options to patients in need.
Enrollment in one of our clinical trials is our primary method for providing patients with access to our investigational drugs prior to their potential approval by regulatory authorities, including the United States Food and Drug Administration, and subsequent commercial availability. Clinical trials are required to demonstrate that an investigational drug meets safety and efficacy standards necessary for approval by regulatory authorities.
To participate in one of our clinical trials, you and your disease must meet specific criteria. As participation in a clinical trial comes with risks, you must also provide your “informed consent” prior to enrolling in a clinical trial.
Our goal is to ensure that appropriate patients can access our investigational drugs at the appropriate time and in the correct manner. We encourage participation in clinical trials and believe that participating in a clinical trial is the best way for patients to access our investigational drugs prior to regulatory approval.
|Selected advanced cancers||Cabiralizumab (FPA008)||
Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)
|Advanced pancreatic cancer||Cabiralizumab (FPA008)||
Cabiralizumab Given With Nivolumab and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
|Pigmented Villonodular Synovitis||Cabiralizumab (FPA008)||
Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)
|Advanced solid tumors||Bemarituzumab (FPA144)||
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients with Advanced Solid Tumors
Gastric / gastroesophageal cancer
FPA144 Combined with Modified FOLFOX6 in Gastric / Gastroesophageal Cancer (FIGHT)
|Advanced solid tumors||FPA150||
FPA150 in Patients with Advanced Solid Tumors (FPA150-001)
|Advanced solid tumors||FPT155||
FPT155 in Patients with Advanced Solid Tumors (FPT155-001)